Fast Market Research

Kenya Pharmaceuticals & Healthcare Report Q3 2014 - New Market Research Report

Recently published research from Business Monitor International, "Kenya Pharmaceuticals & Healthcare Report Q3 2014", is now available at Fast Market Research

 
Repost This

Boston, MA -- (SBWIRE) -- 06/10/2014 -- The growing Kenyan population will support the growth of the country's pharmaceuticals and healthcare industry. While fertility rates have dropped over the last decade, from 5.0 births per woman in 2003 to 4.4 births per woman in 2013, we note that these figures are well above developed state fertility rates. In 2009, the EU-27 average stood at 1.59 live births per woman. However, we note that the country's young population will act as a limiting factor for pharmaceutical demand, presenting a challenge to drugmakers. In 2013, the median age of the population was 18.8 years and by 2050 this will increase marginally to 25.5 years.

View Full Report Details and Table of Contents

Headline Expenditure Projections

- Pharmaceuticals: KES55.29bn (USD642mn) in 2013 to KES64.32bn (USD742mn) in 2014; 16.3% growth in local currency terms and 15.6% in US dollar terms.
- Healthcare: KES178.67bn (USD2.07bn) in 2013 to KES205.30bn (USD2.37bn) in 2014; 14.9% growth in local currency terms and 14.2% in US dollar terms.

Risk/Reward Rating

In BMI's Q314 Pharmaceutical and Healthcare Risk/Reward Ratings (RRRs), Kenya is 20th in the Middle East and Africa (MEA). A large counterfeiting industry, poor healthcare funding, corruption, regulatory deficiencies and a number of other issues will conspire to keep Kenya in a low position in the MEA matrix. Nevertheless, in comparison with many other African markets, most of which are not surveyed by BMI, Kenya offers more commercial promise and a more stable overall business environment.

Key Trends And Developments

Expanding its portfolio of innovative non-voice services, in April 2014 it was reported that Kenya's largest telecoms operator Safaricom has partnered insurance companies Britam and Changamka to launch a health insurance product in the country, specifically targeting the micro-insurance sector. Changamka provides financing mechanisms to deliver affordable healthcare to Kenya's low income population using primarily mobile phone and smart card technologies.

In January 2014 it was reported that the US Agency for International Development (USAID) and GE Healthcare are to partner with Kenya Commercial Bank (KCB), to make KES863mn (USD10mn) in local financing available to small- and medium-sized enterprises for the development of private health facilities, including small clinics, diagnostic centres, and hospitals in Kenya. Since 1896, KCB Bank Group has grown to become the region's largest banking institution with assets of over KES370bn (USD4.5bn), a market capitalisation of over USD1bn and a broad regional network in six Eastern Africa countries.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

- Thailand Pharmaceuticals & Healthcare Report Q3 2014
- Nigeria Pharmaceuticals & Healthcare Report Q3 2014
- Australia Pharmaceuticals & Healthcare Report Q3 2014
- Central America Pharmaceuticals & Healthcare Report Q3 2014
- Mexico Pharmaceuticals & Healthcare Report Q3 2014
- Croatia Pharmaceuticals & Healthcare Report Q3 2014
- Latvia Pharmaceuticals & Healthcare Report Q3 2014
- Algeria Pharmaceuticals & Healthcare Report Q3 2014
- Pakistan Pharmaceuticals & Healthcare Report Q3 2014
- Hungary Pharmaceuticals & Healthcare Report Q3 2014